Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Andrew Attwell
Single Dose Bevacizumab as Treatment for Symptomatic, Corticosteroid-Refractory Pseudoprogression After Chemoradiation Therapy for Newly Diagnosed Glioblastoma: A Case Report
Integrative Cancer Science and Therapeutics
Related publications
Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Boron Neutron Capture Therapy for Newly Diagnosed Glioblastoma
Radiotherapy and Oncology
Nuclear Medicine
Oncology
Radiology
Hematology
Imaging
A Budget Impact Model for the Introduction of Bevacizumab for the Treatment of Newly Diagnosed Glioblastoma Multiforme in the UK
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Addition of Lomustine for Bevacizumab-Refractory Recurrent Glioblastoma
Acta Oncologica
Nuclear Medicine
Radiology
Hematology
Oncology
Medicine
Imaging
A Phase 1 Trial of ABT-510 Concurrent With Standard Chemoradiation for Patients With Newly Diagnosed Glioblastoma
Archives of Neurology
Plasma YKL-40 as a Biomarker for Bevacizumab Efficacy in Patients With Newly Diagnosed Glioblastoma in the Phase 3 Randomized AVAglio Trial
Oncotarget
Oncology
Chemotherapy Plus Concomitant Low-Dose Fractionated Radiotherapy as Second-Line Treatment for Recurrent or Progressive Glioblastoma After Temozolomide-Based Chemoradiation: A Pilot Study.
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Using Temozolomide in Newly Diagnosed Glioblastoma Multiforme – A Single-Centre Experience
Wspolczesna Onkologia
Oncology
Radiology
Nuclear Medicine
Imaging
Ruxolitinib as a Promising Treatment for Corticosteroid-Refractory Graft-Versus -Host Disease
British Journal of Haematology
Hematology
